Ribas, A., Milhem, M. M., Hoimes, C. J., Amin, A., Mehmi, I., Lao, C. D., … Long, G. V. (2018). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. In Journal of Clinical Oncology (Vol. 36, pp. 9513–9513). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.9513

Ribas, Antoni, Mohammed M. Milhem, Christopher J. Hoimes, Asim Amin, Inderjit Mehmi, Christopher D. Lao, Robert Martin Conry, et al. “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” In Journal of Clinical Oncology, 36:9513–9513. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9513.

Ribas A, Milhem MM, Hoimes CJ, Amin A, Mehmi I, Lao CD, et al. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 9513–9513.

Ribas, Antoni, et al. “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 9513–9513. Crossref, doi:10.1200/jco.2018.36.15_suppl.9513.

Ribas A, Milhem MM, Hoimes CJ, Amin A, Mehmi I, Lao CD, Conry RM, Shaheen MF, Jang S, Salama AKS, Deva S, Medina TM, Schmidt EV, Leung ACF, Xing B, Janssen R, Long GV. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 9513–9513.